← Back to APEX IPO ACCESS
OPPORTUNITY PROFILE
Neuralink — The Brain-Computer Interface Market.
Early position in the most ambitious neurotechnology company in the world.
Implied Valuation$8B+
StatusSecondary market
Access TypePre-IPO Secondary
Neuralink’s human trials are underway, with FDA breakthrough designation accelerating its path to commercial deployment. Secondary market activity reflects growing institutional confidence in the long-term medical and consumer applications.
APEX members gain access to verified Neuralink secondaries through compliant SPV structures.
Allocation subject to availability and accredited-investor verification. Past performance does not indicate future results.